Related Experiment Video
Updated: Jul 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Research progress on HLA-G in non-small cell lung cancer]
Rui Li1, Zongwei Guo2, Xiaoyun Zhang3
1Graduate School, Hebei North University, Zhangjiakou 075000; Institute of Respiratory and Critical Medicine, Beijing Key Laboratory of Organ Transplantation and Immunology Regulatory, the 8th Medical Centre of Chinese PLA General Hospital, Beijing 100091, China.
Abstract:
Human leukocyte antigen G (HLA-G) belongs to the non-classic major histocompatibility complex class Ib (MHC Ib) molecule, including membrane and soluble isoforms. HLA-G regulates the function of various immune cells through corresponding receptors. It is one of the important immunological mechanisms of maternal-fetal tolerance and tumor immune escape. Non-small cell lung cancer (NSCLC) patients account for the highest proportion of lung cancer patients and have poor prognoses. Studies have shown that the gene polymorphism and expression level of HLA-G is closely related to the occurrence and development of NSCLC. It is suggested that HLA-G can be used as a potential biomarker for the early diagnosis, subtype differentiation, treatment, and prognosis of NSCLC patients. HLA-G has clinical value as an auxiliary diagnostic basis. An in-depth study of its mechanism can provide new strategies for the diagnosis and treatment of NSCLC patients.

